CDK2 and cancer: The transition from G1 to S phase is driven by CDK2 in complex with its canonical partner cyclin E1 (CCNE1), which is often amplified in various cancers and is associated with worse survival outcomes in patients with breast, ovarian, and other malignancies51–54.